Idiopathic Pulmonary Fibrosis Management Market
Market Insights on Idiopathic Pulmonary Fibrosis Management covering sales outlook, demand forecast & up-to-date key trends
Idiopathic Pulmonary Fibrosis Management Market by Drug Class,Treatment, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033
Idiopathic Pulmonary Fibrosis Management Market Snapshot (2023 to 2033)
The global idiopathic pulmonary fibrosis management market is expected to garner a market value of US$ 3145 Million in 2023 and is expected to accumulate a market value of US$ 3649.90 Million by registering a CAGR of 1.5% in the forecast period 2023 to 2033. The growth of the idiopathic pulmonary fibrosis management market can be attributed to the increasing prevalence of the ailment in males across the globe. The market for idiopathic pulmonary fibrosis management registered a CAGR of 1% in the historical period 2018 to 2022
Idiopathic pulmonary fibrosis (IPF) is a lung disorder with scarring of the lungs from an unknown cause. It is one of the most aggressive forms of idiopathic interstitial pneumonia (IIPs). The majority of patients are male, and the risk of IPF for someone aged 75 years is eight times that of someone aged 45 to 54 years. It is reported that without treatment, the median survival in patients with IPF is 2 to 4 years after diagnosis. Males are more predominantly affected highly with IPF than females. In 2021, there were 121,389 males and 73,488 females affected by IPF in the 7MM.
There are two antifibrotic agents approved for use in IPF. These are pirfenidone and nintedanib (tyrosine kinase inhibitors). Both drugs are known to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies have also decreased exacerbations of IPF with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with nintedanib is diarrhea and pirfenidone rash, photosensitivity, and gastrointestinal discomfort.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 3145 Million |
|
Anticipated Forecast Value (2033) |
US$ 3649.90 Million |
|
Projected Growth Rate (2023 to 2033) |
1.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Idiopathic Pulmonary Fibrosis Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights - the market for Idiopathic pulmonary fibrosis management reflected a value of 1% during the historical period, 2018 to 2022.
The total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM was 194,878 cases in 2021. Gastrointestinal side effects are the most common reason for discontinuing both drugs. According to survey reports, most European physicians are either unaware of these antifibrotic drugs or believe in the wait-and-watch strategies during the progression of IPF. It was found that only 71% of mild IPF-diagnosed patients, 41% of moderate IPF-diagnosed patients, and around 60% of severe IPF-diagnosed patients receive treatment in European counties.
Over the years, some drugs have been investigated to treat IPF cases. Drug molecules such as Pamrevlumab, PRM-151, and Inhaled Treprostinil are in Phase III and have shown positive results in previous clinical studies. In addition to this, some candidates are in Phase II and early stages. Thus, the market for Idiopathic pulmonary fibrosis management is expected to register a CAGR of 1.5% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Idiopathic Pulmonary Fibrosis Management Market?
Increasing prevalence of Idiopathic pulmonary fibrosis in middle-aged men boosting the market growth
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect middle to aged and older adults. It affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis), which increases irreversibly over time.
If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs).
It is a form of interstitial lung disease, primarily involving the interstitium (the tissue and space around the air sacs of the lungs) and not directly affecting the airways or blood vessels. Many other kinds of interstitial lung disease can also cause inflammation and/or fibrosis, and these are treated differently.
Availability of various diagnostic treatments spurring the growth of Idiopathic pulmonary fibrosis management
There are several diagnostic tools available and the consensus guidelines have been well-defined to identify IPF. Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity.
When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like XtoRays is done but when they are not detailed enough to confirm IPF. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.
Careful evaluation of clinical, laboratory, Xtoray data and high resolution computed tomography (HRCT), and at times lung biopsy material to make a confident diagnosis. This is usually done by a respiratory specialist in union with other specialists with an interest in IPF. The diagnosis of IPF relies on the clinician to assimilate and correlate the clinical, laboratory, radiologic, and/or pathology data.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystIdiopathic Pulmonary Fibrosis Treatment
The therapeutic approach to Idiopathic Pulmonary Fibrosis involves both non-pharmacological and pharmacological strategies. The goal of the treatment is to slow disease progression, reduce symptoms, prevent acute exacerbations, and prolong survival. There are two anti-fibrotic agents ESBRIET (Roche) and OFEV (Boehringer Ingelheim) approved for use in IPF. Both drugs are known to slow the disease progression but do not significantly impact mortality.
What are the Challenges Faced by the Idiopathic Pulmonary Fibrosis Management Market?
Lack of awareness and high cost of treatment affecting the market growth
Difficulty in diagnosis is a key factor hindering the growth of the market. As IPF often mimics other lung diseases, making it difficult to diagnose. This can lead to delayed treatment and a poorer prognosis. Furthermore, limited treatment options and no assurance of results are derailing the growth of the market.
In addition, lack of awareness of IPF as it is a rare disease. This can make it difficult for patients to find doctors who are familiar with the disease and can lead to a delay in diagnosis and treatment. Moreover, the high cost of treatment is a burden for patients and their families. All these factors are creating obstacles to the growth of the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Region-Wise Insights
Accelerated Drug Approvals in North America Creating Lucrative Opportunities for Idiopathic Pulmonary Fibrosis Management Market?
High market penetration and increasing prices of the drugs are other factors driving the growth of the market
The highest diagnosed prevalent cases of IPF were accounted for by the USA in 2021, with 94,736 cases in the 7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population. Owing to high market penetration and increasing prices of the drugs are other factors driving the growth of the market. The market is growing rapidly due to accelerated approvals of two drugs in the United States of America. Moreover, the increasing prevalence of IPF is one of the major factors anticipated to boost the market.
Manufacturers offer various programs to improve access among patients. For instance, F. Hoffman La-Roche, Ltd (Genentech) offers Genentech Access to Care Foundation and Esbriet Co-Pay Card Program that covers out-of-pocket expenses and provides Esbriet free of charge for certain household income thresholds. Boehringer Ingelheim offers similar free access and co-pay assistance programs. Thus, North America is expected to possess a 45% market share for the Idiopathic pulmonary fibrosis management market in 2023.
Higher Number of Individuals Suffering from Idiopathic Pulmonary Fibrosis Boosting Market Growth in Europe?
Launch of innovative medications supporting idiopathic pulmonary fibrosis management market growth in Europe
Europe was estimated to be the second-largest market in 2022 owing to the increasing prevalence of IPF. For instance, according to the European Idiopathic Pulmonary Fibrosis Foundation, 30,000 to 35,000 new cases of IPF are diagnosed every year. Moreover, between 80,000 to 111,000 people are living with IPF in Europe. The average life expectancy of patients diagnosed with IPF is 2-5 years.
Among the European countries, Germany had the highest diagnosed prevalent population of IPF with 20,774 cases, followed by the UK with 15,760 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population. In addition, improved healthcare infrastructure along with the availability of innovative medications is expected to drive the growth of the market. Thus, Europe is expected to hold a 40% market share of the Idiopathic pulmonary fibrosis management market in 2023.
Category-Wise Insights
Availability of Wide Range of Medication Making Retail Pharmacies Favorable for Idiopathic Pulmonary Fibrosis Management Market?
Easy purchase of multiple medicines increasing the popularity of retail pharmacies
The availability of both prescription and over-the-counter drugs in retail pharmacies is driving growth in the pulmonary fibrosis treatment market and is expected to continue doing so in the future. This, in turn, makes it convenient for consumers to fill multiple prescriptions and purchase other healthcare products all in one place.
This increase in convenience and access to healthcare services is likely a major factor in the growing popularity of retail pharmacies. Thus, retail pharmacies are expected to possess a 40% market share of the Idiopathic pulmonary fibrosis management market in 2023.
Market Competition
Key players in the idiopathic pulmonary fibrosis management market are Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova Inc, Bristol Myers Squibb Company, Galapagos NV, HoffmanntoLa Roche AG, Neopharm Group, Galecto Biotech, Pfizer Inc, Johnson & Johnson Services, Inc, AstraZeneca
- Boehringer Ingelheim GMBH, a key player in the idiopathic pulmonary fibrosis management market is working on a combination therapy of nintedanib and pirfenidone, which is currently under clinical trial. They also have a pipeline of potential new treatment options for IPF that are currently in preclinical or early-stage development. In addition, Boehringer Ingelheim GMBH is also actively involved in clinical trials to further explore the safety and efficacy of their drugs in IPF treatment.
- Pfizer another key player in the idiopathic pulmonary fibrosis management market is actively involved in clinical trials to further explore the safety and efficacy of their drugs in IPF treatment. The company is also working on the development of a therapy that targets the underlying causes of IPF by modulating the immune system, which is still under research.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 3145 Million |
|
Market Value in 2033 |
US$ 3649.90 Million |
|
Growth Rate |
CAGR of 1.5% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Idiopathic Pulmonary Fibrosis Management Industry Survey
Drug Class:
- Pirfenidone
- Nintedanib
- Interferon Gammato1b
- Others
Treatment:
- Oxygen Therapy
- Lung Transplant
- Others
Route of Administration:
- Oral
- Injectable
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
At what rate did the Idiopathic pulmonary fibrosis management market flourish from 2018 to 2022?
From 2018 to 2022, the Idiopathic pulmonary fibrosis management market grew at a CAGR of 1%
What will be the growth rate of the global Idiopathic pulmonary fibrosis management market during the forecast period?
The global Idiopathic pulmonary fibrosis management market is expected to grow with a 1.5% CAGR during 2023 to 2033.
What will be the projected market size of the Idiopathic pulmonary fibrosis management market by 2033?
As of 2033, the Idiopathic pulmonary fibrosis management market is expected to reach US$ 3649.90 Million
Which distribution channel segment is expected to dominate the global Idiopathic pulmonary fibrosis management market during 2033?
Retail pharmacies are expected to possess 40% market share for Idiopathic pulmonary fibrosis management market in 2023.
How is the North America Idiopathic pulmonary fibrosis management market projected to grow in 2033?
North America is expected to possess 45% market share for Idiopathic pulmonary fibrosis management market in 2023.
How is the Europe Idiopathic pulmonary fibrosis management market projected to grow in 2023?
Asia Pacific Idiopathic pulmonary fibrosis management market size is expected to possess a 40% market share in 2023.
Table of Content
1. Executive Summary | Idiopathic Pulmonary Fibrosis Management Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Pirfenidone 5.3.2. Nintedanib 5.3.3. Interferon Gamma-1b 5.3.4. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 6.3.1. Oxygen Therapy 6.3.2. Lung Transplant 6.3.3. Others 6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 7.3.1. Oral 7.3.2. Injectable 7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. Middle East and Africa (MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Drug Class 10.2.3. By Treatment 10.2.4. By Route of Administration 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Treatment 10.3.4. By Route of Administration 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Class 11.2.3. By Treatment 11.2.4. By Route of Administration 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Treatment 11.3.4. By Route of Administration 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. UK 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Drug Class 12.2.3. By Treatment 12.2.4. By Route of Administration 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Treatment 12.3.4. By Route of Administration 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Drug Class 13.2.3. By Treatment 13.2.4. By Route of Administration 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Treatment 13.3.4. By Route of Administration 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Class 14.2.3. By Treatment 14.2.4. By Route of Administration 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Treatment 14.3.4. By Route of Administration 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Drug Class 15.2.3. By Treatment 15.2.4. By Route of Administration 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Treatment 15.3.4. By Route of Administration 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Class 16.2.3. By Treatment 16.2.4. By Route of Administration 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Class 16.3.3. By Treatment 16.3.4. By Route of Administration 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Class 17.1.2.2. By Treatment 17.1.2.3. By Route of Administration 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Class 17.2.2.2. By Treatment 17.2.2.3. By Route of Administration 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Class 17.3.2.2. By Treatment 17.3.2.3. By Route of Administration 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Class 17.4.2.2. By Treatment 17.4.2.3. By Route of Administration 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Class 17.5.2.2. By Treatment 17.5.2.3. By Route of Administration 17.5.2.4. By Distribution Channel 17.6. UK 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Class 17.6.2.2. By Treatment 17.6.2.3. By Route of Administration 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Class 17.7.2.2. By Treatment 17.7.2.3. By Route of Administration 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Class 17.8.2.2. By Treatment 17.8.2.3. By Route of Administration 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Class 17.9.2.2. By Treatment 17.9.2.3. By Route of Administration 17.9.2.4. By Distribution Channel 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Class 17.10.2.2. By Treatment 17.10.2.3. By Route of Administration 17.10.2.4. By Distribution Channel 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Class 17.11.2.2. By Treatment 17.11.2.3. By Route of Administration 17.11.2.4. By Distribution Channel 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Class 17.12.2.2. By Treatment 17.12.2.3. By Route of Administration 17.12.2.4. By Distribution Channel 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Class 17.13.2.2. By Treatment 17.13.2.3. By Route of Administration 17.13.2.4. By Distribution Channel 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Class 17.14.2.2. By Treatment 17.14.2.3. By Route of Administration 17.14.2.4. By Distribution Channel 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Class 17.15.2.2. By Treatment 17.15.2.3. By Route of Administration 17.15.2.4. By Distribution Channel 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Class 17.16.2.2. By Treatment 17.16.2.3. By Route of Administration 17.16.2.4. By Distribution Channel 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Class 17.17.2.2. By Treatment 17.17.2.3. By Route of Administration 17.17.2.4. By Distribution Channel 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Class 17.18.2.2. By Treatment 17.18.2.3. By Route of Administration 17.18.2.4. By Distribution Channel 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Class 17.19.2.2. By Treatment 17.19.2.3. By Route of Administration 17.19.2.4. By Distribution Channel 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Class 17.20.2.2. By Treatment 17.20.2.3. By Route of Administration 17.20.2.4. By Distribution Channel 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Class 17.21.2.2. By Treatment 17.21.2.3. By Route of Administration 17.21.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Class 18.3.3. By Treatment 18.3.4. By Route of Administration 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Boehringer Ingelheim GMBH 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Biogen 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Novartis AG 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Medicinova Inc. 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Bristol-Myers Squibb Company 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Galapagos NV 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Hoffmann-La Roche AG 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Neopharm Group 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Galecto Biotech 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Pfizer Inc. 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.11. Johnson & Johnson Services, Inc. 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 19.1.12. AstraZeneca 19.1.12.1. Overview 19.1.12.2. Product Portfolio 19.1.12.3. Profitability by Market Segments 19.1.12.4. Sales Footprint 19.1.12.5. Strategy Overview 19.1.12.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 4: Global Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 5: Global Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 6: North America Value (US$ Million) Forecast by Country, 2018 to 2033 Table 7: North America Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 8: North America Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 9: North America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 10: North America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 11: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033 Table 12: Latin America Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 13: Latin America Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 14: Latin America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 15: Latin America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 16: Europe Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: Europe Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 18: Europe Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 19: Europe Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 20: Europe Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 21: South Asia Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: South Asia Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 23: South Asia Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 24: South Asia Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 25: South Asia Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 26: East Asia Value (US$ Million) Forecast by Country, 2018 to 2033 Table 27: East Asia Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 28: East Asia Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 29: East Asia Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 30: East Asia Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 31: Oceania Value (US$ Million) Forecast by Country, 2018 to 2033 Table 32: Oceania Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 33: Oceania Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 34: Oceania Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 35: Oceania Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 36: MEA Value (US$ Million) Forecast by Country, 2018 to 2033 Table 37: MEA Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 38: MEA Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 39: MEA Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 40: MEA Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Value (US$ Million) by Drug Class, 2023 to 2033 Figure 2: Global Value (US$ Million) by Treatment, 2023 to 2033 Figure 3: Global Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 4: Global Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 5: Global Value (US$ Million) by Region, 2023 to 2033 Figure 6: Global Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 7: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 8: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 9: Global Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 10: Global Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 11: Global Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 12: Global Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 13: Global Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 14: Global Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 15: Global Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 16: Global Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 17: Global Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 18: Global Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 19: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 20: Global Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 21: Global Attractiveness by Drug Class, 2023 to 2033 Figure 22: Global Attractiveness by Treatment, 2023 to 2033 Figure 23: Global Attractiveness by Route of Administration, 2023 to 2033 Figure 24: Global Attractiveness by Distribution Channel, 2023 to 2033 Figure 25: Global Attractiveness by Region, 2023 to 2033 Figure 26: North America Value (US$ Million) by Drug Class, 2023 to 2033 Figure 27: North America Value (US$ Million) by Treatment, 2023 to 2033 Figure 28: North America Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 29: North America Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 30: North America Value (US$ Million) by Country, 2023 to 2033 Figure 31: North America Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 32: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 33: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 34: North America Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 35: North America Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 36: North America Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 37: North America Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 38: North America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 39: North America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 40: North America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 41: North America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 42: North America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 43: North America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 44: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 45: North America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 46: North America Attractiveness by Drug Class, 2023 to 2033 Figure 47: North America Attractiveness by Treatment, 2023 to 2033 Figure 48: North America Attractiveness by Route of Administration, 2023 to 2033 Figure 49: North America Attractiveness by Distribution Channel, 2023 to 2033 Figure 50: North America Attractiveness by Country, 2023 to 2033 Figure 51: Latin America Value (US$ Million) by Drug Class, 2023 to 2033 Figure 52: Latin America Value (US$ Million) by Treatment, 2023 to 2033 Figure 53: Latin America Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 54: Latin America Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 55: Latin America Value (US$ Million) by Country, 2023 to 2033 Figure 56: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 57: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 58: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 59: Latin America Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 60: Latin America Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 61: Latin America Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 62: Latin America Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 63: Latin America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 64: Latin America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 65: Latin America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 66: Latin America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 67: Latin America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 68: Latin America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 69: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 70: Latin America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 71: Latin America Attractiveness by Drug Class, 2023 to 2033 Figure 72: Latin America Attractiveness by Treatment, 2023 to 2033 Figure 73: Latin America Attractiveness by Route of Administration, 2023 to 2033 Figure 74: Latin America Attractiveness by Distribution Channel, 2023 to 2033 Figure 75: Latin America Attractiveness by Country, 2023 to 2033 Figure 76: Europe Value (US$ Million) by Drug Class, 2023 to 2033 Figure 77: Europe Value (US$ Million) by Treatment, 2023 to 2033 Figure 78: Europe Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 79: Europe Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 80: Europe Value (US$ Million) by Country, 2023 to 2033 Figure 81: Europe Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 82: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 83: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 84: Europe Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 85: Europe Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 86: Europe Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 87: Europe Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 88: Europe Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 89: Europe Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 90: Europe Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 91: Europe Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 92: Europe Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 93: Europe Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 94: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 95: Europe Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 96: Europe Attractiveness by Drug Class, 2023 to 2033 Figure 97: Europe Attractiveness by Treatment, 2023 to 2033 Figure 98: Europe Attractiveness by Route of Administration, 2023 to 2033 Figure 99: Europe Attractiveness by Distribution Channel, 2023 to 2033 Figure 100: Europe Attractiveness by Country, 2023 to 2033 Figure 101: South Asia Value (US$ Million) by Drug Class, 2023 to 2033 Figure 102: South Asia Value (US$ Million) by Treatment, 2023 to 2033 Figure 103: South Asia Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 104: South Asia Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 105: South Asia Value (US$ Million) by Country, 2023 to 2033 Figure 106: South Asia Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 107: South Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 108: South Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 109: South Asia Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 110: South Asia Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 111: South Asia Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 112: South Asia Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 113: South Asia Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 114: South Asia Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 115: South Asia Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 116: South Asia Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 117: South Asia Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 118: South Asia Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 119: South Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 120: South Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 121: South Asia Attractiveness by Drug Class, 2023 to 2033 Figure 122: South Asia Attractiveness by Treatment, 2023 to 2033 Figure 123: South Asia Attractiveness by Route of Administration, 2023 to 2033 Figure 124: South Asia Attractiveness by Distribution Channel, 2023 to 2033 Figure 125: South Asia Attractiveness by Country, 2023 to 2033 Figure 126: East Asia Value (US$ Million) by Drug Class, 2023 to 2033 Figure 127: East Asia Value (US$ Million) by Treatment, 2023 to 2033 Figure 128: East Asia Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 129: East Asia Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 130: East Asia Value (US$ Million) by Country, 2023 to 2033 Figure 131: East Asia Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 132: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 133: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 134: East Asia Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 135: East Asia Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 136: East Asia Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 137: East Asia Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 138: East Asia Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 139: East Asia Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 140: East Asia Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 141: East Asia Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 142: East Asia Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 143: East Asia Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 144: East Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 145: East Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 146: East Asia Attractiveness by Drug Class, 2023 to 2033 Figure 147: East Asia Attractiveness by Treatment, 2023 to 2033 Figure 148: East Asia Attractiveness by Route of Administration, 2023 to 2033 Figure 149: East Asia Attractiveness by Distribution Channel, 2023 to 2033 Figure 150: East Asia Attractiveness by Country, 2023 to 2033 Figure 151: Oceania Value (US$ Million) by Drug Class, 2023 to 2033 Figure 152: Oceania Value (US$ Million) by Treatment, 2023 to 2033 Figure 153: Oceania Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 154: Oceania Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 155: Oceania Value (US$ Million) by Country, 2023 to 2033 Figure 156: Oceania Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 157: Oceania Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 158: Oceania Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 159: Oceania Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 160: Oceania Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 161: Oceania Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 162: Oceania Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 163: Oceania Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 164: Oceania Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 165: Oceania Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 166: Oceania Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 167: Oceania Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 168: Oceania Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 169: Oceania Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 170: Oceania Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 171: Oceania Attractiveness by Drug Class, 2023 to 2033 Figure 172: Oceania Attractiveness by Treatment, 2023 to 2033 Figure 173: Oceania Attractiveness by Route of Administration, 2023 to 2033 Figure 174: Oceania Attractiveness by Distribution Channel, 2023 to 2033 Figure 175: Oceania Attractiveness by Country, 2023 to 2033 Figure 176: MEA Value (US$ Million) by Drug Class, 2023 to 2033 Figure 177: MEA Value (US$ Million) by Treatment, 2023 to 2033 Figure 178: MEA Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 179: MEA Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 180: MEA Value (US$ Million) by Country, 2023 to 2033 Figure 181: MEA Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 182: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 183: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 184: MEA Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 185: MEA Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 186: MEA Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 187: MEA Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 188: MEA Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 189: MEA Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 190: MEA Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 191: MEA Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 192: MEA Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 193: MEA Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 194: MEA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 195: MEA Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 196: MEA Attractiveness by Drug Class, 2023 to 2033 Figure 197: MEA Attractiveness by Treatment, 2023 to 2033 Figure 198: MEA Attractiveness by Route of Administration, 2023 to 2033 Figure 199: MEA Attractiveness by Distribution Channel, 2023 to 2033 Figure 200: MEA Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
